Cargando…

Sex Differences in Time to Treat and Outcomes for Gliomas

BACKGROUND: Gliomas are the most common type of primary malignant brain tumor in adults, representing one third of all primary and central nervous system (CNS) tumors and 80% of malignant tumors diagnosed in the Western world. Epidemiological data indicate that the overall incidence and mortality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stabellini, Nickolas, Krebs, Halle, Patil, Nirav, Waite, Kristin, Barnholtz-Sloan, Jill S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933512/
https://www.ncbi.nlm.nih.gov/pubmed/33680971
http://dx.doi.org/10.3389/fonc.2021.630597
_version_ 1783660627562070016
author Stabellini, Nickolas
Krebs, Halle
Patil, Nirav
Waite, Kristin
Barnholtz-Sloan, Jill S.
author_facet Stabellini, Nickolas
Krebs, Halle
Patil, Nirav
Waite, Kristin
Barnholtz-Sloan, Jill S.
author_sort Stabellini, Nickolas
collection PubMed
description BACKGROUND: Gliomas are the most common type of primary malignant brain tumor in adults, representing one third of all primary and central nervous system (CNS) tumors and 80% of malignant tumors diagnosed in the Western world. Epidemiological data indicate that the overall incidence and mortality of cancer is higher in males, while females have a better prognosis. The goal of this study is to determine whether there are sex differences in the time to treat and clinical outcomes in patients with glioma METHODS: Glioblastoma (GB) and Lower Grade Glioma (LGG) patients were defined per the Central Brain Tumor Registry of the United States (CBTRUS) from the National Cancer Database (NCDB) for diagnosis years 2004 to 2016. Associations between sex and time to treatment variables as well as associations between sex and multiple clinical outcomes were assessed using univariable and multivariable models. RESULTS: A total of 176,100 patients were used for analysis (124,502 GBM and 51,598 LGG). Males had a statistically significant association with >7 days to surgery (OR = 1.09, CI 1.05–1.13, p < 0.001) but this association was not observed in the multivariable model (OR = 1.05, CI 0.96–1.16, p = 0.25). After adjustment for key variables including time to treat variables, males with GB and LGG had a higher risk of death (HR = 1.11, CI 1.09–1.13, p < 0.001, HR = 1.09, CI 1.03–1.15, p < 0.001; respectfully). Sex differences in 90-day mortality for GBM were not found after adjustment (OR for males = 0.99, CI 0.91–1.08, p = 0.93). For LGG, both the univariable and multivariable logistic regression models showed no sex differences in 90-day mortality (OR for males = 1.03, CI 0.94–1.12, p = 0.45; multivariable OR for males = 0.81, CI 0.62–1.06, p = 0.13). CONCLUSIONS: Based on NCDB data, there were no statistically significant differences in time to treatment between males and females, however males had a higher proportion of GB and LGG as well as a higher risk of death compared to females.
format Online
Article
Text
id pubmed-7933512
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79335122021-03-06 Sex Differences in Time to Treat and Outcomes for Gliomas Stabellini, Nickolas Krebs, Halle Patil, Nirav Waite, Kristin Barnholtz-Sloan, Jill S. Front Oncol Oncology BACKGROUND: Gliomas are the most common type of primary malignant brain tumor in adults, representing one third of all primary and central nervous system (CNS) tumors and 80% of malignant tumors diagnosed in the Western world. Epidemiological data indicate that the overall incidence and mortality of cancer is higher in males, while females have a better prognosis. The goal of this study is to determine whether there are sex differences in the time to treat and clinical outcomes in patients with glioma METHODS: Glioblastoma (GB) and Lower Grade Glioma (LGG) patients were defined per the Central Brain Tumor Registry of the United States (CBTRUS) from the National Cancer Database (NCDB) for diagnosis years 2004 to 2016. Associations between sex and time to treatment variables as well as associations between sex and multiple clinical outcomes were assessed using univariable and multivariable models. RESULTS: A total of 176,100 patients were used for analysis (124,502 GBM and 51,598 LGG). Males had a statistically significant association with >7 days to surgery (OR = 1.09, CI 1.05–1.13, p < 0.001) but this association was not observed in the multivariable model (OR = 1.05, CI 0.96–1.16, p = 0.25). After adjustment for key variables including time to treat variables, males with GB and LGG had a higher risk of death (HR = 1.11, CI 1.09–1.13, p < 0.001, HR = 1.09, CI 1.03–1.15, p < 0.001; respectfully). Sex differences in 90-day mortality for GBM were not found after adjustment (OR for males = 0.99, CI 0.91–1.08, p = 0.93). For LGG, both the univariable and multivariable logistic regression models showed no sex differences in 90-day mortality (OR for males = 1.03, CI 0.94–1.12, p = 0.45; multivariable OR for males = 0.81, CI 0.62–1.06, p = 0.13). CONCLUSIONS: Based on NCDB data, there were no statistically significant differences in time to treatment between males and females, however males had a higher proportion of GB and LGG as well as a higher risk of death compared to females. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7933512/ /pubmed/33680971 http://dx.doi.org/10.3389/fonc.2021.630597 Text en Copyright © 2021 Stabellini, Krebs, Patil, Waite and Barnholtz-Sloan http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Stabellini, Nickolas
Krebs, Halle
Patil, Nirav
Waite, Kristin
Barnholtz-Sloan, Jill S.
Sex Differences in Time to Treat and Outcomes for Gliomas
title Sex Differences in Time to Treat and Outcomes for Gliomas
title_full Sex Differences in Time to Treat and Outcomes for Gliomas
title_fullStr Sex Differences in Time to Treat and Outcomes for Gliomas
title_full_unstemmed Sex Differences in Time to Treat and Outcomes for Gliomas
title_short Sex Differences in Time to Treat and Outcomes for Gliomas
title_sort sex differences in time to treat and outcomes for gliomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933512/
https://www.ncbi.nlm.nih.gov/pubmed/33680971
http://dx.doi.org/10.3389/fonc.2021.630597
work_keys_str_mv AT stabellininickolas sexdifferencesintimetotreatandoutcomesforgliomas
AT krebshalle sexdifferencesintimetotreatandoutcomesforgliomas
AT patilnirav sexdifferencesintimetotreatandoutcomesforgliomas
AT waitekristin sexdifferencesintimetotreatandoutcomesforgliomas
AT barnholtzsloanjills sexdifferencesintimetotreatandoutcomesforgliomas